In the IMAGYN050 trial, it was shown that almost 2/3 of newly diagnosed stage III or IV ovarian carcinomas had a moderate PD-L1 expression (assessed by SP142 clone on immune cells), which was associated with the worst prognosis, mainly on immune cells rather than tumor cells. This evidence concerns the gene CD274 and neoplasm.